These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 33289420)
1. Tissue and interspecies comparison of catechol- Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420 [TBL] [Abstract][Full Text] [Related]
2. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869 [TBL] [Abstract][Full Text] [Related]
4. Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells. Grünig D; Felser A; Duthaler U; Bouitbir J; Krähenbühl S Toxicol Sci; 2018 Aug; 164(2):477-488. PubMed ID: 29688484 [TBL] [Abstract][Full Text] [Related]
5. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662 [TBL] [Abstract][Full Text] [Related]
6. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Detrait ER; Carr GV; Weinberger DR; Lamberty Y Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286 [TBL] [Abstract][Full Text] [Related]
7. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Kaakkola S; Gordin A; Männistö PT Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624 [TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase. Forester SC; Lambert JD Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases. Lv X; Wang XX; Hou J; Fang ZZ; Wu JJ; Cao YF; Liu SW; Ge GB; Yang L Toxicol Appl Pharmacol; 2016 Jun; 301():42-9. PubMed ID: 27089846 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800 [TBL] [Abstract][Full Text] [Related]
11. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. Engelbrecht I; Petzer JP; Petzer A Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034 [TBL] [Abstract][Full Text] [Related]
12. COMT inhibition in the treatment of Parkinson's disease. Ruottinen HM; Rinne UK J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337 [TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Kaakkola S Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160 [TBL] [Abstract][Full Text] [Related]
14. Coupling S-adenosylmethionine-dependent methylation to growth: Design and uses. Luo H; Hansen ASL; Yang L; Schneider K; Kristensen M; Christensen U; Christensen HB; Du B; Özdemir E; Feist AM; Keasling JD; Jensen MK; Herrgård MJ; Palsson BO PLoS Biol; 2019 Mar; 17(3):e2007050. PubMed ID: 30856169 [TBL] [Abstract][Full Text] [Related]
15. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease. Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315 [TBL] [Abstract][Full Text] [Related]
16. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Forsberg MM; Huotari M; Savolainen J; Männistö PT Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340 [TBL] [Abstract][Full Text] [Related]
17. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related]
18. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells. Grünig D; Felser A; Bouitbir J; Krähenbühl S Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites. Liang SC; Ge GB; Xia YL; Pei-Pei D; Ping W; Qi XY; Cai-Xia T; Ling Y Xenobiotica; 2017 Jun; 47(6):498-504. PubMed ID: 27435571 [TBL] [Abstract][Full Text] [Related]
20. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety. de Beer AD; Legoabe LJ; Petzer A; Petzer JP Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]